Karima Sharif recently joined Benchworks’ leadership team as senior vice president and media director to lead all strategic media planning and nonpersonal promotion (NPP) services. She has launched, consulted, and managed 300-plus NPP/paid media campaigns for over 75 pharmaceutical and medical device brands in over 25 therapeutic categories. Her experience covers audience segmentation and strategy, digital media expertise, sales/partnership building, account/brand management, and leadership/mentoring.
It’s time to move your marketing tactics beyond the expected. Rapidly evolving technologies have opened several new avenues that can help you not only reach more clients and prospects, but also strengthen your relationships with them. Here are the top 5 trends you should learn more about.
You probably know a lot about your clients and prospects—the industries they work in, their position within their organization, the organization’s key business sectors, and annual income. Having that data helps you create your marketing strategy and plan. But there’s more to building a strong relationship with clients than amassing key data points.
The clinical trial landscape is becoming crowded. Currently there are 284,058 registered studies with trial sites in the United States and overseas, according to ClinicalTrials.gov. The sheer number of trials competing for patients, investors, and investigators makes it more difficult to attract people and resources for your trial. To move forward, you’ll need to differentiate. […]
What led to your decision to join Benchworks? Over the last few years, I’ve felt a need to break out of the mold and challenge myself across the board—creatively, in leadership, strategic thinking, and even in entrepreneurial ways. I was fortunate to discover this fantastic opportunity to join a growing organization at a very […]
Cardiovascular disease is the leading cause of death among women. Yet the number of women who take part in clinical trials that address treatment of cardiovascular disease is markedly lower than the number of men included in these trials. One recent study found that in trials of 36 cardiovascular medications, only 34% of participants overall were women.